Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11660330

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

VACCINEX, INC. · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654145

Combination therapy involving diaryl macrocyclic compounds

TURNING POINT THERAPEUTICS, INC. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654157

Methods and compositions for cancer therapies that include delivery of halogenated thymidi

Shuttle Pharmaceuticals, Inc. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654193

Cancer treatment combinations

The Regents of the University of California · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11648211

Nanoencapsulated combination drug formulations

Northwestern University · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633385

Combination compositions for treatment of cancer

RedHill Biopharma Ltd. · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11618784

Anti-CD47 combination therapy

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11612575

Combination therapies with disulfiram

Spring Discovery, Inc. · Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11590154

Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for t

RedHill Biopharma Ltd. · Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11572408

Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modula

VACCINEX, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11564927

Therapeutic compositions, combinations, and methods of use

VERASTEM, INC. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559583

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542312

IL-2 superagonists in combination with anti-PD-1 antibodies

Medicenna Therapeutics Inc. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11529340

Combination for treating pain

Regents of the University of Minnesota · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11529360

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11510929

Mitigation of epileptic seizures by combination therapy using benzodiazepines and neuroste

The Regents of the University of California · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497781

Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovi

CG ONCOLOGY, INC. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497713

Combination taxoid nanoemulsion with immunotherapy in cancer

Northwestern University · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11491145

Combination therapies comprising targeted therapeutics

Madrigal Pharmaceuticals, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11491215

Antigenic combinations against Francisella bacteria and related nanolipoprotein particles,

The Regents of the University of New Mexico · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11478428

Combinations of beta-lactam compounds and probenecid and uses thereof

Iterum Therapeutics International Limited · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464856

Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15

Julius-Maximilians-Universitat Wurzburg · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted